Cabergoline NDC 50090-3157

NDC codes

FDA NDC Directory

Product NDC (as listed)50090-3157Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50090-3157Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50090-3157-0	50090315700	1 BOTTLE in 1 CARTON (50090-3157-0) / 8 TABLET in 1 BOTTLEMarketed from Oct 6, 2017

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cabergoline
Generic name (nonproprietary): cabergoline
Active ingredients: Cabergoline — .5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: A-S Medication Solutions
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077750
Marketing start: Mar 7, 2007
Listing expires: Dec 31, 2027
Other FDA classes: Ergolines (Chemical structure)
Identifiers: Product ID 50090-3157_9cfd8ff7-be0f-4956-b637-63d68606b856SPL ID 9cfd8ff7-be0f-4956-b637-63d68606b856SPL set ID c9f0b576-d5e5-4e3e-bb5c-3574d75d9907RxCUI 199703UNII LL60K9J05T
Pharmacologic class: Ergot Derivative

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450090315700 followed by a unit qualifier and the quantity

Package 50090-3157-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 19, 2026.

Indications (excerpt from the label)

Cabergoline tablets are an ergot derivative indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas in adults. Limitations of Use Avoid use of cabergoline tablets for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions [see Warnings and Precautions (5.4)]. Cabergoline tablets are an ergot derivative indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas in adults. ( 1 ) Limitations of Use Avoid use of cabergoline tablets for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious advers…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 077750

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 077750
Product	Strength	Form · route	Labeler	Product NDC
Cabergoline	Cabergoline .5 mg/1	TabletOral	Teva Pharmaceuticals USA, Inc.	0093-5420